Contact

Our portfolio

Rsouth Antibodies

Rsouth Antibodies has developed a therapeutic antibody for Respiratory Syncytial Virus (RSV) that has been licensed to MedImmune (now AstraZeneca). AstraZeneca has finalized clinical validation and obtained regulatory approval for this antibody that is now marketed by Sanofi as Nirsevimab for prevention of RSV in infants. Since RSV infection have been on the rise again since 2022, many lives have already been saved by treatment with Nirsevimab.

  • Institute: Amsterdam UMC
Industry: Infectious Disease, Therapeutics
  • Founding year: 2018
Visit website

Want to get in contact about Rsouth Antibodies?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Oefenweb.nl
Developing adaptive online learning systems.
Regenesance
Engineering antibodies to treat neurodegenerative and immune diseases.
Sightcorp
Specializing in AI-powered audience intelligence, Sightcorp provides automated facial analysis and emotion recognition technology.
Kepler Vision Technologies
Improving elderly care with Night Nurse, an AI-powered patient monitoring system.
Oefenweb.nl
Developing adaptive online learning systems.
Regenesance
Engineering antibodies to treat neurodegenerative and immune diseases.
Sightcorp
Specializing in AI-powered audience intelligence, Sightcorp provides automated facial analysis and emotion recognition technology.
Kepler Vision Technologies
Improving elderly care with Night Nurse, an AI-powered patient monitoring system.
Explore full AAV portfolio
Contact